NCT01498900已完成不适用
A Multi-center, Prospective, Non-interventional Evaluation of Efficacy, Safety and Convenience of Using NovoNorm® in the Treatment of Type 2 Diabetic Patients in Routine Clinical Practice
适应症
干预措施
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 30,554
- 试验地点
- 1
- 主要终点
- HbA1c (glycosylated haemoglobin)
研究概览
简要总结
This study is conducted in Africa and Asia. The aim of this study is to evaluate the efficacy, safety and convenience of using repaglinide (NovoNorm®) in type 2 diabetes management in routine clinical practice.
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Prospective
入排标准
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Type 2 diabetes
- •Newly diagnosed or not adequately controlled with current therapy
排除标准
- 未提供
研究组 & 干预措施
Repaglinide
干预措施: repaglinide (Drug)
结局指标
主要结局
HbA1c (glycosylated haemoglobin)
次要结局
- Fasting Plasma Glucose (FPG)
- Postprandial glucose values
- Incidence of hypoglycaemia
- Adverse drug reactions (ADR)
研究者
研究点 (1)
Loading locations...
相似试验
已完成
不适用
Observational Study on Efficacy, Safety and Convenience of Using Mixtard® 30 NovoLet® Alone or Combined With OHA in Treatment of Type 2 Diabetes in Routine Clinical PracticeDiabetes Mellitus, Type 2DiabetesNCT01492166Novo Nordisk A/S1,935
已完成
不适用
Observational Study to Evaluate Safety, Efficacy and Convenience of Using NovoMix® 30 FlexPen® in Type 2 DiabetesDelivery SystemsDiabetesDiabetes Mellitus, Type 2NCT00715663Novo Nordisk A/S1,584
已完成
不适用
Observational Study of Biphasic Insulin Aspart 30 Alone or in Combination With Oral Hypoglycaemic Agents in Subjects With Type 2 DiabetesDiabetesDiabetes Mellitus, Type 2NCT01536600Novo Nordisk A/S33,010
已完成
不适用
Observational Study to Evaluate the Safety of Levemir® in DiabetesDiabetesDiabetes Mellitus, Type 2Diabetes Mellitus, Type 1NCT00659295Novo Nordisk A/S51,170
已完成
不适用
A Study to Evaluate Safety and Efficacy of NovoSeven® in Patients With Glanzmann's Thrombasthenia in JapanCongenital Bleeding DisorderGlanzmann's DiseaseNCT01876745Novo Nordisk A/S4